Chris Martin, ADC Therapeutics CEO
August 26, 2021 09:27 AM EDT
Deals

ADC Ther­a­peu­tics sells off roy­al­ty share for lead an­ti­body-drug con­ju­gate in $325M deal

Kyle Blankenship

ADC Ther­a­peu­tics will re­ceive $225 mil­lion in cash and an ad­di­tion­al $100 mil­lion in near-term mile­stones as part of a roy­al­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times